GW Pharmaceuticals is seeking approval in the U.K. and Spain for Sativex, a cannabis-based multiple sclerosis drug, after clinical trials proved the treatment's effectiveness in reducing spasticity in patients who failed to respond to other therapies. The company plans to seek clearance for the product in other European markets next year.

Full Story:

Related Summaries